Treatment approach could reduce risk of superficial vein thrombosis

Researchers explored whether low-dose apixaban may minimize the risk of superficial vein thrombosis.

In a post-hoc analysis published as a research letter in JAMA Cardiology, the authors used data from the HI-PRO clinical trial, in which 600 adult patients with provoked deep vein thrombosis and/or pulmonary embolism who had one or more risk factors for recurrence were randomly assigned to receive extended, oral low-dose apixaban or placebo.

After a follow-up of 12 months, the authors found that the low-dose apixaban group experienced a lower risk of first symptomatic superficial vein thrombosis, fewer concomitant deep vein thromboses or pulmonary emboli, and fewer first isolated symptomatic superficial vein thromboses compared with those in the placebo group.

The findings suggested that treatment of venous thromboembolism with low-dose apixaban could reduce the risk of superficial vein thrombosis. Despite the positive findings, there were no statistically significant differences in the proportion of isolated symptomatic superficial vein thrombosis events between the low-dose apixaban and placebo groups. Therefore, further studies are needed to validate the results of the study.

Read more: JAMA Cardiology

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.